Loading clinical trials...
Loading clinical trials...
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Conditions
Interventions
Carboplatin
Paclitaxel
+2 more
Locations
17
United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
City of Hope South Pasadena
South Pasadena, California, United States
City of Hope Upland
Upland, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Kansas Clinical Research Center
Fairway, Kansas, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Start Date
December 2, 2021
Primary Completion Date
October 6, 2024
Completion Date
October 1, 2026
Last Updated
January 30, 2026
NCT05969860
NCT06078709
NCT04704661
NCT05677490
NCT04511039
NCT05041153
Lead Sponsor
NRG Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions